Wegovy® Online

Wegovy® is a once-weekly injectable medication made by Novo Nordisk whose active ingredient is semaglutide, a GLP-1 receptor agonist. It is FDA-approved for chronic weight management and for cardiovascular risk reduction in eligible adults. If a provider prescribes it, it is filled through a licensed pharmacy — it is the brand-name product, not a compounded preparation.

Yes. Wegovy is FDA-approved for chronic weight management in adults with obesity (BMI 30+), or overweight (BMI 27+) with at least one weight-related condition, as an adjunct to diet and exercise.

In adults with established cardiovascular disease and obesity or overweight, Wegovy is FDA-approved to reduce the risk of cardiovascular death, heart attack, and stroke, based on the SELECT trial, where it lowered that risk by about 20% versus placebo.

You can start the process online through telehealth. A licensed provider reviews your information and, if appropriate, issues a prescription that a licensed pharmacy fills and ships to you. It always requires a prescription.

DripVitals offers Wegovy at a single price of $1,399/mo, which includes the consultation, prescription review if appropriate, ongoing support, and free discreet shipping.

Wegovy is the FDA-approved, brand-name product made by Novo Nordisk, and brand-name pharmaceutical pricing is set by the manufacturer's list price. Other treatments on our site are priced differently because they are different products.

DripVitals plans are cash-pay and do not bill insurance. Some commercial insurance plans do cover Wegovy for weight management, and Novo Nordisk offers a savings program for eligible patients — checking your pharmacy benefits before deciding how to fill a prescription is worthwhile.

They contain the same active ingredient, semaglutide, and are both made by Novo Nordisk, but they are approved for different uses: Wegovy for chronic weight management and cardiovascular risk reduction, Ozempic for type 2 diabetes.

Wegovy's active ingredient is semaglutide, which activates GLP-1 receptors; Zepbound's is tirzepatide, which activates both GIP and GLP-1 receptors. In the SURMOUNT-5 head-to-head obesity trial, tirzepatide produced greater average weight loss than semaglutide over 72 weeks — though Wegovy is the option with a proven cardiovascular risk-reduction indication. They are made by different companies, and a provider can advise which fits your situation.

As a once-weekly injection under the skin of the abdomen, thigh, or upper arm using a prefilled single-dose pen, on the same day each week, at any time of day, with or without food.

If you miss your weekly dose, take it within a few days if you can; if your next dose is near, skip the missed one and resume your schedule. Never double up, and follow your provider's instructions.

Many people notice reduced appetite within the first weeks. Visible weight change usually builds over 8–12 weeks as treatment is adjusted.

In the STEP 1 trial, adults without diabetes lost about 15% of body weight on average over 68 weeks, alongside lifestyle changes, and roughly one in three lost 20% or more. Individual results vary.

In the STEP 4 study, participants who stopped semaglutide gradually regained much of the weight, while those who continued maintained their loss. Obesity is treated as a chronic condition, and your provider can help you plan a long-term strategy.

Wegovy is not approved for type 2 diabetes — that indication belongs to Ozempic, the semaglutide brand approved for diabetes. If you have type 2 diabetes, tell your provider; it shapes which product and plan is appropriate.

Nausea, diarrhea, vomiting, constipation, stomach pain, headache, fatigue, and indigestion are the most common, especially during treatment changes, and usually ease over time.

Most are mild and temporary. Rare but serious effects exist, including pancreatitis, gallbladder problems, kidney injury from dehydration, and serious allergic reactions; seek care promptly for severe symptoms, and report new or worsening mood changes to your provider.

Eat smaller, lower-fat meals, stop when full, stay hydrated, and avoid heavy or greasy foods. Gradual treatment changes also help; tell your provider if it persists.

It can, because it slows digestion. Fiber, fluids, and regular movement usually help; ask your provider if it continues.

Rapid weight loss from any cause can sometimes trigger temporary shedding. Adequate protein and nutrition help, and it typically resolves.

In animal studies semaglutide caused thyroid C-cell tumors; human risk is unknown. It should not be used by anyone with a personal or family history of medullary thyroid carcinoma or MEN 2.

People with a personal or family history of medullary thyroid carcinoma or MEN 2, anyone with a prior serious allergic reaction to semaglutide, and people who are pregnant or breastfeeding generally should not. Your provider reviews your full history.

No. Wegovy is not recommended during pregnancy or breastfeeding — weight loss offers no benefit during pregnancy and may harm the fetus. Tell your provider if you are pregnant or planning to be.

Moderate alcohol may worsen nausea or blood sugar swings. Discuss your habits with your provider.

It can, particularly insulin and sulfonylureas (raising low-blood-sugar risk in people with diabetes) and oral medications whose absorption is affected by slower digestion. It should not be combined with other semaglutide or GLP-1 products. Share your full medication list with your provider.

Yes — Wegovy is approved for use alongside a reduced-calorie diet and increased physical activity, and it works best with reasonable nutrition, adequate protein, and regular movement.

Keep pens refrigerated and protected from light, and never freeze them. Follow the labeling and your pharmacy's instructions, including any allowance for limited time at room temperature.

Yes. Wegovy requires a valid prescription from a licensed provider; it is not available over the counter.

You complete a secure questionnaire, a licensed provider reviews it, and if appropriate they issue a prescription — all without an in-person visit.

The approved indication covers a BMI of 30+, or 27+ with a weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or sleep apnea. A provider makes the final call.

Eligibility is based on the approved BMI and health criteria, not cosmetic goals. A provider determines whether treatment is appropriate for you.

Obesity is treated as a chronic condition, so many people use it long-term under supervision. Your provider helps plan duration and maintenance.

Often yes, under provider guidance, with an appropriate transition plan. Don't switch on your own — your provider will plan it.

Wegovy is an FDA-approved medication with a well-studied active molecule, but like all prescription medicines it carries risks, including a boxed warning. A provider weighs the benefits and risks for you.

Only obtain medication through a licensed provider and a licensed pharmacy. Counterfeit or gray-market pens sold without a prescription are illegal, unregulated, and unsafe.

If a provider determines you aren't a candidate, you are not charged for medication. Review the specific plan terms during checkout.

Availability varies by state and can change with regulations. Your eligibility is confirmed during the online consultation and at checkout.

Contact your provider. They may adjust your treatment or recommend strategies to manage symptoms. Seek urgent care for severe symptoms.

Complete the short online intake, get reviewed by a licensed provider, and if approved your medication ships to your door. Tap Get Started to begin.